营收、净利大幅增长！一图读懂恒瑞医药2024年半年度报告
注释：
1.Caicun Zhou,et al.2024ELCC Abstract61.
2.Yau T,Park JW,Finn RS,et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate459):a randomised,multicentre,open-label,phase3trial.Lancet Oncol2022;23:77–90.
3.Finn RS,Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894–905.
4.Kelley RK,Rimassa L,Cheng A-L,et al.Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312):a multicentre,open-label,randomised,phase3trial.Lancet Oncol2022;23:995–1008.
5.Llovet JM,Kudo M,Merle P,et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP-002):a randomised,double-blind,phase3trial Lancet Oncol.2023Dec;24(12):1399-1410.
6.Ren Z,Xu J,Bai Y,et al.Sintilimab plus a bevacizumab biosimilar(IBI305)versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32):a randomised,open-label,phase2–3study.Lancet Oncol.2021Jul;22(7):977-990.
7.Abou-Alfa GK,Lau G,Kudo M,et al.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid.2022Aug;1(8):EVIDoa2100070.
| 研发创新|
| 国际化|
| 重磅奖项|
| 社会公益|